Brooklyn Investment Group Takes Position in Insulet Co. (NASDAQ:PODD)

Brooklyn Investment Group bought a new position in Insulet Co. (NASDAQ:PODD) during the third quarter, Holdings Channel reports. The fund bought 717 shares of the medical instruments supplier’s stock, valued at approximately $167,000.

Other institutional investors also recently modified their holdings of the company. Marshall Wace LLP purchased a new position in Insulet during the second quarter valued at $99,978,000. Baillie Gifford & Co. boosted its stake in Insulet by 30.8% in the 2nd quarter. Baillie Gifford & Co. now owns 1,886,062 shares of the medical instruments supplier’s stock worth $380,607,000 after purchasing an additional 443,783 shares in the last quarter. Mizuho Securities USA LLC grew its position in Insulet by 5,928.1% during the 3rd quarter. Mizuho Securities USA LLC now owns 325,821 shares of the medical instruments supplier’s stock valued at $75,835,000 after purchasing an additional 320,416 shares during the last quarter. Charles Schwab Investment Management Inc. increased its stake in Insulet by 43.8% during the 3rd quarter. Charles Schwab Investment Management Inc. now owns 636,265 shares of the medical instruments supplier’s stock valued at $148,091,000 after purchasing an additional 193,839 shares in the last quarter. Finally, Westfield Capital Management Co. LP raised its holdings in Insulet by 27.6% in the third quarter. Westfield Capital Management Co. LP now owns 754,872 shares of the medical instruments supplier’s stock worth $175,697,000 after buying an additional 163,388 shares during the last quarter.

Insulet Trading Up 0.2 %

Shares of Insulet stock opened at $266.92 on Thursday. Insulet Co. has a 1-year low of $160.19 and a 1-year high of $279.40. The company’s fifty day simple moving average is $242.59 and its 200-day simple moving average is $212.36. The stock has a market capitalization of $18.72 billion, a PE ratio of 45.71, a P/E/G ratio of 4.08 and a beta of 1.22. The company has a debt-to-equity ratio of 1.21, a current ratio of 3.68 and a quick ratio of 2.80.

Analyst Upgrades and Downgrades

A number of equities research analysts have recently commented on PODD shares. BTIG Research increased their price target on shares of Insulet from $260.00 to $270.00 and gave the company a “buy” rating in a report on Friday, November 8th. Raymond James increased their target price on Insulet from $213.00 to $260.00 and gave the company an “outperform” rating in a research note on Monday, October 14th. Barclays lifted their target price on Insulet from $220.00 to $234.00 and gave the stock an “equal weight” rating in a report on Monday, November 11th. Sanford C. Bernstein assumed coverage on Insulet in a report on Wednesday, November 6th. They set an “outperform” rating and a $300.00 price target on the stock. Finally, Citigroup lifted their price objective on Insulet from $250.00 to $275.00 and gave the stock a “buy” rating in a report on Tuesday, October 1st. Three research analysts have rated the stock with a hold rating and twelve have assigned a buy rating to the company’s stock. According to MarketBeat, the company currently has an average rating of “Moderate Buy” and an average target price of $253.27.

About Insulet

Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes. The company's Omnipod platform includes the Omnipod 5 Automated Insulin Delivery System (Omnipod 5) which includes a proprietary AID algorithm embedded in the Pod that integrates with a third-party continuous glucose monitor to obtain glucose values through wireless bluetooth communication; Omnipod DASH that features a bluetooth enabled Pod that is controlled by a smartphone-like Personal Diabetes Manager with a color touch screen user interface; and Omnipod GO, a standalone, wearable, insulin delivery system that provides a fixed rate of continuous rapid-acting insulin for 72 hours.